STOCKS TELEGRAPH

Tag: MIRA Pharmaceuticals

  • 3 Stocks That Could Shift Higher: Mira Pharmaceuticals (MIRA), Concord Medical Services (CCM), Cardiol Therapeutics (CRDL)

    3 Stocks That Could Shift Higher: Mira Pharmaceuticals (MIRA), Concord Medical Services (CCM), Cardiol Therapeutics (CRDL)

    Healthcare and biotechnology companies remain at the forefront of investor interest as advancements in drug development and precision medicine continue to reshape the industry landscape. Companies demonstrating clinical progress, operational momentum, and differentiated therapeutic approaches are increasingly being evaluated for their long-term commercial potential.

    Mira Pharmaceuticals Inc (MIRA)

    Mira Pharmaceuticals Inc (NASDAQ: MIRA) opened the trading on May 26, 2026, with a bit cautious approach as it glided -1.81% to $0.97. During the day, the stock rose to $0.99 and sank to $0.95. Taking a more long-term approach, MIRA posted a 52-week range of $0.90-$2.45.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 211.56%. Meanwhile, its Annual Earnings per share during the time were -211.56%.  This publicly-traded company’s shares outstanding now amount to $42.02 million, simultaneously with a float of $35.08 million. The organization now has a market capitalization of $40.93 million.

    Concord Medical Services ADR (CCM)

    Concord Medical Services ADR (NYSE: CCM) started the day on May 26, 2026, with a price decrease of -0.41% at $4.89. During the day, the stock rose to $5.13 and sank to $4.54. Taking a long-term approach, CCM posted a 52-week range of $3.18-$10.77.

    It was noted that the giant of the Healthcare sector posted annual sales growth of 33.20% over the last 5 years. Meanwhile, its Annual Earnings per share during the time was 33.20%.  This publicly-traded company’s shares outstanding now amount to $2.82 million, simultaneously with a float of $2.38 million. The organization now has a market capitalization of $13.79 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to build a broader cardiovascular growth strategy through the development of next-generation therapies aimed at large and underserved disease markets. By expanding beyond recurrent pericarditis, the company is positioning itself to address chronic cardiac conditions where inflammation and fibrosis contribute significantly to disease progression.

    Market Momentum

    As of May 26, 2026, CRDL closed at $1.30, down 1.52%, with trading volume of 324,616 shares compared to an average volume of 695,298 shares. The company currently maintains a market capitalization of $149.854M and a beta of 0.43, reflecting relatively moderate volatility for a small-cap biotech company. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.31 suggests substantial upside potential tied to future pipeline advancement and clinical milestones.

    Pipeline Development: CRD-38

    Cardiol is developing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience while expanding applicability into broader cardiovascular indications, including heart failure. The therapy is intended to target inflammation and fibrosis, biological mechanisms strongly associated with worsening cardiac function and progressive heart disease.

    Large Market Opportunity

    Heart failure remains one of the largest cardiovascular markets globally, affecting millions of patients and generating substantial healthcare costs annually. Despite multiple approved therapies, unmet need persists for treatments capable of directly addressing inflammatory and fibrotic pathways associated with disease progression and long-term cardiac decline.

    Outlook

    As CRD-38 advances toward future clinical development, the program could emerge as an important secondary value driver for Cardiol. Continued progress across the broader pipeline may strengthen the company’s strategic positioning within cardiovascular biotechnology.

  • Stock Soars For MIRA Pharmaceuticals After Major Neuropathic Pain Study

    Stock Soars For MIRA Pharmaceuticals After Major Neuropathic Pain Study

    The stock price of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) has increased significantly, with shares rising 19.45% to $2.21 in the current market. This growing trend confirms MIRA’s status as a pioneer in cutting-edge medicines and comes after the release of a ground-breaking finding in the management of neuropathic pain.

    MIRA Pharmaceuticals’ Highlights Breakthrough Efficacy

    In a recent pre-clinical study conducted on rats, MIRA Pharmaceuticals unveiled that its novel oral ketamine analog, Ketamir-2, exhibited remarkable efficacy in reversing neuropathic pain. Utilizing a nerve ligation model at Pharmaseed Ltd, the study sought to mimic human neuropathic pain and focused specifically on mechanical allodynia.

    The results were compelling: Ketamir-2 not only reduced pain significantly at low doses but also achieved complete normalization of pain thresholds at higher doses, marking a 100% reversal of the neuropathic pain signal. This finding is particularly significant when contrasted with traditional oral ketamine, which failed to deliver similar results under the same conditions.

    Future Studies and Potential Implications

    Encouraged by these promising results, MIRA Pharmaceuticals is advancing its research to assess Ketamir-2’s potential in treating other conditions, including cancer-induced depression and neuropathic pain. With the potential to show efficacy in human trials as early as 2025, the business is confident that these investigations might result in quicker regulatory approvals and creative clinical research designs.

    MIRA Revolutionizing the Standard of Care for Neuropathic Pain

    The successful development of ketamir-2 represents a significant advancement for both MIRA Pharmaceuticals and the broader field of neurologic and neuropsychiatric drug research. Many patients have considerable reductions in quality of life due to neuropathic pain, which has historically been linked to few and frequently ineffective therapeutic choices.

    The research conducted by MIRA Pharmaceuticals indicates that Ketamir-2 may provide a safer, more readily available, and more efficacious substitute, which has the potential to revolutionize the current standard of treatment. Moreover, the ability to administer Ketamir-2 orally without the severe psychotropic side effects typically associated with ketamine underscores its potential as a pioneering treatment, offering renewed hope to patients with few therapeutic options.

  • MIRA Pharmaceuticals (MIRA) Surges In After-Hours Following Key Developments

    In a sudden twist of events, MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) experienced a staggering 82% surge in its stock price during after-hours trading, almost doubling its value to an impressive $1.73. This significant leap comes on the heels of a rather subdued trading day where the stock showed minimal movement, slipping by a mere 0.1%.

    Promising Momentum Driven by Recent Regulatory Filing

    The sudden spike in MIRA’s stock price appears to be intricately tied to a recent 8k filing, illuminating crucial updates regarding the company’s innovative drug candidate, MIRA1a. This oral pharmaceutical marijuana compound holds the potential in addressing the debilitating effects of anxiety and cognitive decline, particularly prevalent in individuals grappling with early-stage dementia.

    Notably, regulatory authorities have determined that neither MIRA1a nor its counterpart, Ketamir-2, fall under controlled substance classifications.

    Breakthrough Discovery Ignites Optimism

    MIRA Pharmaceuticals recently unveiled a groundbreaking revelation stemming from collaborative discussions with its manufacturing partners. This revelation centers on the identification of a novel molecule, MIRA-55, distinct from the originally intended MIRA1a compound.

    Initial assessments suggest that MIRA-55 boasts heightened potency and efficacy compared to its predecessor, paving the way for a provisional patent application aimed at securing global protection.

    Strategic Alliances and Future Prospects

    The strategic partnership forged last month between MIRA Pharmaceuticals and Pharmaseed Ltd., a renowned clinical research organization specializing in neurological disorders, heralds a new chapter in the pursuit of innovative therapeutics.

    Together, they embark on a journey to evaluate Ketamir-2, a revolutionary ketamine analog, with aspirations of delivering rapid relief to individuals grappling with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). This synergistic collaboration underscores MIRA’s commitment to pioneering solutions for mental health challenges.

    Conclusion

    The surge in MIRA Pharmaceuticals’ stock price mirrors growing investor confidence buoyed by significant advancements in the company’s pharmaceutical portfolio. With the emergence of the potent MIRA-55 molecule and strategic alliances firmly established, MIRA Pharmaceuticals stands at the forefront of revolutionizing the treatment landscape for neurologic and neuropsychiatric disorders.

    As stakeholders eagerly anticipate further developments, the trajectory of MIRA Pharmaceuticals underscores its unwavering dedication to reshaping the future of healthcare.

  • What Helped MIRA Pharmaceuticals Recover In Extended Session

    What Helped MIRA Pharmaceuticals Recover In Extended Session

    MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) witnessed a notable upswing of 7.04% in its stock value, reaching $3.42 during the extended trading session on Wednesday. This surge contributed to the partial recovery of MIRA Pharmaceuticals stock, mitigating an 18.08% loss in the regular session and concluding at $3.20. The impetus for this positive momentum was an announcement by MIRA Pharmaceuticals heralding a paradigm shift.

    In a groundbreaking revelation, MIRA Pharmaceuticals (MIRA) disclosed pioneering insights into the cognitive enhancement effects of MIRA1a in normal mice. This unveiling occurred during a presentation at the Grand Rounds of the University of Louisville’s Christine Lee Brown Envirome Institute. This significant finding was delivered by Dr. Adam Kaplin, MD, PhD, President and Chief Scientific Officer at MIRA Pharmaceuticals. He is also an Adjunct Faculty member at Johns Hopkins School of Medicine.

    His presentation focused on the unique properties of THC and MIRA1a, an innovative analog of THC, which were the focus of Dr. Kaplin’s research on psychotropic drug development. The research highlighted that while THC displayed a biphasic response, being therapeutic at low doses but toxic at high doses, MIRA1a exhibited remarkable stability, even at elevated doses, without inducing any toxic side effects.

    Moreover, MIRA1a demonstrated a twofold increase in the performance of normal adult mice in learning and memory tests, underscoring its potential to enhance cognitive abilities beyond conventional thresholds. The revelation of MIRA1a’s profound cognitive enhancement, evident even after a single dose, signifies a transformative breakthrough in neuropsychiatric research.

    This landmark discovery solidifies MIRA Pharmaceuticals’ position at the forefront of innovative developments in psychotropic drug research. With an unwavering commitment to seizing industry-defining opportunities, MIRA Pharmaceuticals stands poised to capitalize on a vast market potential. The company concentrates its efforts on addressing anxiety and neuropathic pain within the expansive traditional neurological markets valued at over $90 billion.

    According to Dr. Kaplin, cognitive impairment can be treated in a revolutionary way, especially in the early stages of dementia, according to his findings. MIRA1a has consistent therapeutic effects, even at high doses, making it a promising candidate to treat neuropsychiatric disorders.